SHARE

NY Con Man Admits Scamming $3.5M From Elderly Investors In NJ, Elsewhere For Heart Attack Pill

A convicted con artist from Long Island admitted in federal court in Trenton on Monday that he scammed investors in a purportedly revolutionary new aspirin -- most of them elderly -- out of $3.5 million that he used as his own personal piggybank.

Donald A. Milne III

Donald A. Milne III

Photo Credit: FACEBOOK (Island Raceway & Hobby)

Donald A. Milne III, a 57-year-old repeat offender from Massapequa, defrauded more than 70 victims from throughout the country who though they'd invested in Instaprin, which he touted as a “fast-acting form of powdered aspirin that could instantly stop heart attacks and strokes," Acting U.S. Attorney Rachael A. Honig said.

He used the money instead for a Caribbean vacation, boating expenses, divorce payments, clothing, and spa treatments -- and to sustain and operate Island Raceway & Hobby Inc., a now-defunct remote-controlled toy race car business in Lindenhurst, she said.

A much smaller portion of the money went toward paying other investors in a “Ponzi-scheme fashion,” Honig said.

Milne – who’d pleaded guilty to investment fraud charges in a previous case more than 20 years ago -- told the investors this time that their money was being used to cover “normal day-to-day operating expenses” of Instaprin, as well as “the costs involved in developing and commercializing its products,” the U.S. attorney said.

It wasn't, she said.

Milne also lied when he told the victims that he’d assembled a “very strong world-renowned board of directors and medical advisory board” that included industry leaders in fields of science and finance, Honig said.

The “false and misleading” assertions didn’t end there, she said.

Honig said that Milne -- the founder, president, and chief executive officer of Instaprin Pharmaceuticals -- also told investors that Instaprin:

  • had been approved by the U.S. Food and Drug Administration (FDA); as nearing a product launch and public stock offering;
  • had contracted with a New Jersey research company for an FDA-approved clinical trial;
  • was in negotiations with large pharmaceutical corporations for “imminent” joint busines ventures.

The Securities and Exchange Commission filed a civil complaint against Milne and Instaprin in U.S. District Court in New Jersey in May 2019.

The complaint says that Milne “portrayed himself as an experienced professional in the pharmaceutical industry who was on the cusp of turning his investors’ investments into riches,” when he was, in fact, “a convicted felon who preyed on and defrauded unsuspecting investors.”

Milne already had a history: He was sentenced to probation in 2000 after admitting that he took bribes as a New York boiler-room broker in another securities scam, records show.

Milne resolved the recent complaint by agreeing to final judgments “permanently enjoining (him) and Instaprin from violating the charged provisions of the federal securities laws, ordering full disgorgement, prejudgment interest, and civil penalties,” Honig said.

Rather than face criminal prosecution, he took a deal from the government, pleading guilty Monday to securities fraud via video conference.

U.S. District Judge Michael A. Shipp accepted the plea and scheduled sending for March 24, 2022.

Honig credited special agents of the FBI Trenton Resident Agency with the investigation leading to the plea, secured by Assistant U.S. Attorney J. Brendan Day, the attorney-in-charge of her Trenton Office, and Assistant U.S. Attorney Heather Suchorsky of her Economic Crimes Unit in Newark.

Honig also thanked the SEC’s Philadelphia Regional Office for “substantial assistance” on the case.

to follow Daily Voice Hackensack and receive free news updates.

SCROLL TO NEXT ARTICLE